Gary S. Jacob, Ph.D.

Chairman of the Board and CEO

Gary Jacob, Ph.D., has served as our President, Chief Executive Officer and a Director since July 2008. He is a co-inventor of Synergy’s uroguanylin-based GI platform technology for functional GI disorders and inflammatory bowel disease. He has over 25 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations and business development. Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and Chairman of the Board of ContraVir Pharmaceuticals, Inc. since May 2013. He served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. He also served as Chief Scientific Officer of Synergy from 1999 to 2003. Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology and Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. From 1986 to 1990, he managed the G.D. Searle Glycobiology Group located at Oxford University, England.

Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

Thomas H. Adams, Ph.D.

Independent Director since 2008

Thomas H. Adams, Ph.D. has served as a Director of our company since July 2008.

Since June 2005, Dr. Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS since April 2006. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989, and Chairman of Trovagene, Inc., a public diagnostics company. He has significant public-company experience serving as a director of Biosite Diagnostics, Inc., a publicly held medical research firm, from 1989 to 1998 and as a director of Invitrogen, a publicly held company that develops, manufactures and markets research tools and products, from 2000 to 2002. Dr. Adams currently serves as a director of La Jolla Pharmaceutical Co. (NASDAQ: LJPC), a publicly held company that develops and markets novel therapeutics for antibody-mediated autoimmune diseases.

Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.

John P. Brancaccio

Independent Director since 2008

John P. Brancaccio, a retired C.P.A., has served as a Director of our company since July 2008. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. as well as a director of Trovagene, Inc.

Melvin K. Spigelman, M.D.

Independent Director since 2008

Melvin K. Spigelman, M.D. has served as a Director of our company since August 2008.

Dr. Spigelman is Chief Executive Officer of the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. Before joining the Global Alliance for TB Drug Development, Dr. Spigelman was President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 1992 to 2001, Dr. Spigelman served as a Vice President and head of R&D at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma. Dr. Spigelman has been a director of The Medicines Company since 2005.

Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine; and is board certified in internal medicine, medical oncology and preventive medicine.

Alan F. Joslyn, Ph.D.

Director since 2008

Alan F. Joslyn, Ph.D. has served as a Director of our company since October 2008.

Dr. Joslyn is currently the Chief Executive Officer of Edusa Pharmaceuticals, a privately held biotechnology company. Prior to his association with Edusa, he served as the President and Chief Executive Officer of Mt. Cook Pharma from 2007 to 2009, and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004, Dr. Joslyn held a number of leadership positions within Johnson & Johnson, focusing on development of gastroenterology products including Propulsid®, Motilium®, Aciphex® and prucalopride. Prior to joining Johnson & Johnson, Dr. Joslyn was engaged in clinical research at Glaxo from 1988 to 1995.

Dr. Joslyn received his B.S. in Medicinal Chemistry, B.A. in Biology and Ph.D. in Biochemical Pharmacology from the State University of New York at Buffalo.

Timothy S. Callahan

Independent Director since 2015

Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization. From 2013-2014 he served as Senior Vice President, Commercial Operations where he played a leadership role in the transformation of the Actavis brand business into a $7B/yr division with a focus in Gastroenterology, Women’s Health, Urology, Dermatology, and other specialty markets. From 2010-2012, Mr. Callahan served as Vice President, International Brands & Biologics Marketing at Actavis, and from 2003-2009 he served as Vice President, Sales & Marketing for the company’s Nephrology division. Earlier in his career, Mr. Callahan held positions of increasing responsibility in commercial leadership at Watson Pharmaceuticals and Schein Pharmaceutical. Mr. Callahan was educated at Cornell University and holds a Bachelor of Science degree in Applied Economics and Business Management.

Richard J. Daly

Independent Director since 2015

Mr. Daly has over 20 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. Mr. Daly is Chairman and CEO of Neuralstem, Inc and emerging biotechnology company with clinical programs in the CNS space. In the past he was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca. During his 13-year tenure at Takeda Pharmaceuticals, he served as Executive Vice President with P&L responsibility for businesses across the U.S., Canada, and Central/South America. Earlier in his career, he served in the sales organizations at Merrell-Dow Pharmaceuticals (now part of Sanofi) and TAP Pharmaceuticals (formerly a division of Abbott Labs) in sales, marketing, operations and senior leadership positions at TAP and Takeda. Mr. Daly currently serves on the board of Catalyst Pharmaceuticals. Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University’s Kellogg School of Management.